Monday, 2 April 2012

Inflammatory Breast Cancer-Chemotherapy-Trastuzumab-Bevacizumab

[Articles] Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Neoadjuvant treatment with bevacizumab, trastuzumab, and chemotherapy was efficacious and well tolerated in patients with previously untreated primary inflammatory breast cancer. Further confirmation of use of bevacizumab in inflammatory breast cancer is needed. (Source: The Lancet Oncology) read more..

No comments:

Post a Comment